Coax, COX and cola

Dowden, John S

doi:10.5694/j.1326-5377.2003.tb05613.x

Topics

General medicine

Pharmaceutical preparations

Manufacturers’ claims in well funded marketing campaigns cannot replace the test of time

Australian Prescriber, Deakin, ACT.

Correspondence:

Competing interests:

Australian Prescriber is published by the National Prescribing Service. John Dowden is an unpaid director of Therapeutic Guidelines Ltd, and a member of the Editorial Advisory Board of Australian Medicines Handbook.

1. Analysis section. Pharmaceutical Benefits Branch. PBS expenditure and prescriptions January 2000 to December 2000. Available at: www.health.gov.au/pbs/general/pubs/pbbexp/pbdec00/index.htm (accessed Sep 2003).
2. Pharmaceutical Benefits Pricing Authority. Annual report for the year ended 30 June 2001. Canberra: AGPS, 2001.
3. Kerr SJ, Mant A, Horn FE, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407.<eMJA full text>
4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
6. Cutts C, LaCase A, Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Br J Clin Pharmacol 2002; 54: 522-527.
7. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
8. Budenholzer BR. Rofecoxib did not provide unequivocal benefit over traditional NSAIDs [letter]. BMJ 2002; 325: 161.
9. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in clinical trial of celecoxib [letter]. JAMA 2001; 286: 2398.
10. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
11. Wooldridge M. Relief for half a million arthritis sufferers [media release]. Canberra: Commonwealth Department of Health and Aged Care; 1 June 2000. Available at www.health.gov.au/mediarel/yr2000/mw/mw20048.htm (accessed Sep 2003).
12. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2003; 53: 120-125.
13. National Institute for Health Care Management Research and Educational Foundation. Prescription drugs and mass media advertising 2000. Washington: NIHCM Foundation, 2001.
14. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust 2002; 177: 291-293. <eMJA full text>
15. Health Research Group. New research results on safety of newly approved drugs causes Health Research Group to extend five-year waiting rule to seven years. Worst Pills Best Pills 2002; 8: 41-43.

Online responses are no longer available. Please refer to our instructions for authors page for more information.